20 research outputs found
Unaccounted uncertainty from qPCR efficiency estimates entails uncontrolled false positive rates
BACKGROUND: Accurate adjustment for the amplification efficiency (AE) is an important part of real-time quantitative polymerase chain reaction (qPCR) experiments. The most commonly used correction strategy is to estimate the AE by dilution experiments and use this as a plug-in when efficiency correcting the ΔΔC(q). Currently, it is recommended to determine the AE with high precision as this plug-in approach does not account for the AE uncertainty, implicitly assuming an infinitely precise AE estimate. Determining the AE with such precision, however, requires tedious laboratory work and vast amounts of biological material. Violation of the assumption leads to overly optimistic standard errors of the ΔΔC(q), confidence intervals, and p-values which ultimately increase the type I error rate beyond the expected significance level. As qPCR is often used for validation it should be a high priority to account for the uncertainty of the AE estimate and thereby properly bounding the type I error rate and achieve the desired significance level. RESULTS: We suggest and benchmark different methods to obtain the standard error of the efficiency adjusted ΔΔC(q) using the statistical delta method, Monte Carlo integration, or bootstrapping. Our suggested methods are founded in a linear mixed effects model (LMM) framework, but the problem and ideas apply in all qPCR experiments. The methods and impact of the AE uncertainty are illustrated in three qPCR applications and a simulation study. In addition, we validate findings suggesting that MGST1 is differentially expressed between high and low abundance culture initiating cells in multiple myeloma and that microRNA-127 is differentially expressed between testicular and nodal lymphomas. CONCLUSIONS: We conclude, that the commonly used efficiency corrected quantities disregard the uncertainty of the AE, which can drastically impact the standard error and lead to increased false positive rates. Our suggestions show that it is possible to easily perform statistical inference of ΔΔC(q), whilst properly accounting for the AE uncertainty and better controlling the false positive rate
Unaccounted uncertainty from qPCR efficiency estimates entails uncontrolled false positive rates
Proof of the concept to use a malignant B cell line drug screen strategy for identification and weight of melphalan resistance genes in multiple myeloma
In a conceptual study of drug resistance we have used a preclinical model of malignant B-cell lines by combining drug induced growth inhibition and gene expression profiling. In the current report a melphalan resistance profile of 19 genes were weighted by microarray data from the MRC Myeloma IX trial and time to progression following high dose melphalan, to generate an individual melphalan resistance index. The resistance index was subsequently validated in the HOVON65/GMMG-HD4 trial data set to prove the concept. Biologically, the assigned resistance indices were differentially distributed among translocations and cyclin D expression classes. Clinically, the 25% most melphalan resistant, the intermediate 50% and the 25% most sensitive patients had a median progression free survival of 18, 32 and 28 months, respectively (log-rank P-value  = 0.05). Furthermore, the median overall survival was 45 months for the resistant group and not reached for the intermediate and sensitive groups (log-rank P-value  = 0.003) following 38 months median observation. In a multivariate analysis, correcting for age, sex and ISS-staging, we found a high resistance index to be an independent variable associated with inferior progression free survival and overall survival. This study provides clinical proof of concept to use in vitro drug screen for identification of melphalan resistance gene signatures for future functional analysis
Predicting response to multidrug regimens in cancer patients using cell line experiments and regularised regression models
BACKGROUND: Patients suffering from cancer are often treated with a range of chemotherapeutic agents, but the treatment efficacy varies greatly between patients. Based on recent popularisation of regularised regression models the goal of this study was to establish workflows for pharmacogenomic predictors of response to standard multidrug regimens using baseline gene expression data and origin specific cell lines. The proposed workflows are tested on diffuse large B-cell lymphoma treated with R-CHOP first-line therapy. METHODS: First, B-cell cancer cell lines were tested successively for resistance towards the chemotherapeutic components of R-CHOP: cyclophosphamide (C), doxorubicin (H), and vincristine (O). Second, baseline gene expression data were obtained for each cell line before treatment. Third, regularised multivariate regression models with cross-validated tuning parameters were used to generate classifier and predictor based resistance gene signatures (REGS) for the combination and individual chemotherapeutic drugs C, H, and O. Fourth, each developed REGS was used to assign resistance levels to individual patients in three clinical cohorts. RESULTS: Both classifier and predictor based REGS, for the combination CHO, were of prognostic value. For patients classified as resistant towards CHO the risk of progression was 2.33 (95% CI: 1.6, 3.3) times greater than for those classified as sensitive. Similarly, an increase in the predicted CHO resistance index of 10 was related to a 22% (9%, 36%) increased risk of progression. Furthermore, the REGS classifier performed significantly better than the REGS predictor. CONCLUSIONS: The regularised multivariate regression models provide a flexible workflow for drug resistance studies with promising potential. However, the gene expressions defining the REGSs should be functionally validated and correlated to known biomarkers to improve understanding of molecular mechanisms of drug resistance. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12885-015-1237-6) contains supplementary material, which is available to authorized users
Melphalan resistance gene index validation by clinical outcome.
<p>The individual RIs were assigned from gene expression data of the HOVON 65/GMMG-HD4 trial dividing tumor samples into groups of sensitive patients with low 0–25% RI, intermediate RI from 25–75% and resistant patients with the highest 75–100% RI. The impact of this assignment was subsequently evaluated with respect to PFS and overall OS as illustrated by log relative hazard for PFS (1A) and OS (1B) as a function of the individual RI levels. The P-values are the maximum likelihood tests for no RCS-association between log Relative Hazard and the RI and the dashed lines represent 95% confidence intervals. A landmark Kaplan-Meier analysis was performed from the time of HDM and we found that resistant, intermediate and sensitive patient groups had a median PFS of 18, 32 and 28 months, respectively (1C). The OS for the resistant group had a median of 45 months but not reached for the intermediate and resistant groups (1D) following a median observation time of 38 months. The P-values are the log-rank-test results for no difference between the estimated survival curves.</p
Univariate and multivariate Cox proportional hazard models.
<p>The sensitive and intermediate RI groups were merged into a common non-resistant group of patients. The redefined non-resistant (RI 0–75%) and resistant (RI 75–100%) groups were analysed by univariate (P-value  = 0.003 for PFS and P-value  = 0.00089 for OS) as well as a multivariate Cox proportional hazard models documenting an association with PFS and OS (P-value of 0.0063 and 0.0025), independent of age, sex and ISS staging. The appropriateness of the Cox proportional hazard models using the dichotomized resistance index was checked using cumulative martingale residuals.</p
The melphalan RI in patients treated without HDM.
<p>Illustration of the negative validation of the approach in a data set from156 relapsed MM patients treated without HDM by inclusion into the APEX trial (18) that compared single-agent bortezomib to high-dose dexamethasone. The individual RIs were assigned from each patients' gene expression data of the APEX trial dividing tumor samples into groups of sensitive patients with the low 0–25% RI, intermediate RI between 25–75% and resistant patients with the highest 75–100% RI. The impact of this assignment was subsequently evaluated with respects to PFS and overall OS as illustrated by log relative hazard for PFS (5A) and OS (5B) as a function of the individual RI levels. The P-values are the maximum likelihood tests for no RCS-association between log Relative Hazard and the RI and the dashed lines represent 95% confidence intervals. A landmark Kaplan-Meier analysis was performed from the time of treatment start which found that resistant, intermediate and sensitive patient groups had no significant differences with respect to the prediction of PFS as well as OS from time of relapse therapy. The P-values are the log-rank-test results for no difference in survival curves.</p
The melphalan RI differ between TC classes.
<p>The translocation and cyclin D defined TC classification involving early oncogenic events were applied to the HOVON65/GMMG-HD4 data set and in panel A) each of the 8 classes of tumours showed different melphalan RI levels (P-value  = 0.00025). In panel B) these classes were grouped into two groups with good or poor prognosis with different melphalan RI levels (P-value  = 0.0028).</p
The poor diagnostic accuracy illustrated by ROC curves.
<p>The diagnostic accuracy of the RI to predict the PFS and OS was evaluated by ROC curves. The true positive rate (sensitivity) was plotted as a function of the false positive rate (1- specificity) for a series of time dependent cut-off points illustrating the level of discrimination is quantified by area under curve (AUC) for OS and PFS being poor between 60–70%.</p